100 completed, 21 unknown, 8 not yet recruiting, 8 recruiting. 43 Not applicable, 32 Phase 3, 23 Phase 2, 20 Phase 4, 17 Phase 1.
Follow Bacterial Vaginosis: new trials by email Literature Review of Bacterial Vaginosis trials Research Report on Bacterial Vaginosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test New Investigational Drugs (LCFA-01and LC103) for Bacterial Vaginosis (BV) Treatment metronidazole (MTZ)+ LCFA-01 placebo + LC103 placebo, metronidazole (MTZ)+ LCFA-01 + LC103 placebo, metronidazole (MTZ)+ LC103 + LCFA-01 placebo - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Massachusetts General Hospital | 280 | 2027-02-03 | 2026-10-15 |
| Prevention of Vaginal Cuff Infection After Hysterectomy by Addition of Vaginal Clindamycin Clindamycin Vaginal Gel - Surgical Site Infection, Vaginal Cuff Cellulitis | Enrolling by invitation | Baylor Research Institute | 900 | 2026-12-01 | 2026-10-22 | |
| AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth Vaginal flora abnormalities screening and quantification using molecular biology technique, Azithromycin, Ceftriaxone - Bacterial Vaginosis, Vaginal Dysbiosis | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 1794 | 2026-10-01 | 2026-08-27 |
| Photobiomodulation With Blue LED in Recurrent Bacterial Vaginosis Metronidazole, Blue Light-Emitting Diode (LED) - Bacterial Vaginosis | Not applicable | Not yet recruiting | Patricia Lordelo | 40 | 2026-09-30 | 2026-09-23 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment Blue LED Photobiomodulation - Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis | Not applicable | Not yet recruiting | Patricia Lordelo | 150 | 2026-07-30 | 2026-07-13 |
| Efficacy and Safety of a Vaginal Ovule Medical Device for Bacterial Vaginosis and Candidal Vaginitis (ROVUL25). Class IIa vaginal medical device supplied as vaginal ovules, intended as an adjuvant in prevention of vaginal infections and symptoms., Placebo. - Bacterial Vaginosis, Candidal Vaginitis | Not applicable | Not yet recruiting | ROELMI HPC | 80 | 2026-07-09 | 2026-07-14 |
| Impact of Clinician-administered Vaginal Live Biotherapeutic Product LC106 - Bacterial Vaginosis | Early Phase 1 | Completed | Caroline Mitchell | 26 | 2026-04-28 | 2026-09-29 |
| The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study Vaginal lactoferrin, Usual care - Bacterial Vaginosis, Candida Vaginal | Not applicable | Recruiting | Guy's and St Thomas' NHS Foundation Trust | 114 | 2026-04-16 | 2026-05-29 |
| Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients BPR-101 capsules:Investigational product for the treatment of BV, Placebo：matching the investigational product in appearance, dosage form, and route of administration - Bacterial Vaginosis | Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 80 | 2026-04-15 | 2026-03-19 |
| Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis | Phase 2 / Phase 3 | Not yet recruiting | Kaneka Americas Holding Inc. | 160 | 2026-04-01 | 2026-04-14 |
| A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women GenSci142, Placebo GenSci142 - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 30 | 2025-12-01 | 2025-12-24 |
| Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial Vaginosis Multi-Gyn FemiTotal - Bacterial Vaginosis, Vaginal Candidiasis | Not applicable | Recruiting | Karo Pharma AB | 80 | 2025-10-22 | 2026-10-02 |
| Light Treatment of Vaginal Infections in Reproductive Age Women Vaginal light therapy - Once, Vaginal Light Therapy - Once, Vaginal Light Therapy - Twice - Bacterial Vaginosis, Vulvovaginal Candidiases | Not applicable | Completed | UVISA Health ApS | 38 | 2025-06-05 | 2026-02-17 |
| Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP - Bacterial Vaginosis, Candida Vaginitis | Completed | Hoffmann-La Roche | 738 | 2024-12-30 | 2026-10-16 | |
| Clinical Protocol CERN Feasibility Study Cern Device - Bacterial Vaginosis, Fungal Vaginal Infections | Not applicable | Recruiting | Cern Corporation | 9 | 2024-11-06 | 2025-04-18 |
| A Clinical Study to Determine the Safety and Efficacy of an Oral Probiotic Supplementation to Improve Bacterial Vaginosis in Females MetSheFlora - Vaginal Health - Bacterial Vaginosis | Not applicable | Completed | NovoBliss Research Pvt Ltd | 14 | 2024-10-21 | 2025-03-03 |
| A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections. Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement - Bacterial Vaginosis, Yeast Infection | Not applicable | Completed | Happy V | 120 | 2024-10-04 | 2026-08-13 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis BNT331, Placebo - Bacterial Vaginosis | Phase 1 | Completed | BioNTech SE | 102 | 2024-07-01 | 2026-10-05 |
Showing 20 of 150. Sign in to see all of them.
Vaginosis, Bacterial (150) · Candidiasis, Vulvovaginal (19) · Vaginitis (15) · Premature Birth (9) · Trichomonas Vaginitis (8) · Vaginal Diseases (7) · Candidiasis (5) · Gonorrhea (5) · HIV Infections (5) · Recurrence (5) · Sexually Transmitted Diseases (4) · Urinary Tract Infections (4) · Bacterial Infections (3) · Chlamydia Infections (3) · Communicable Diseases (3)
Female Urogenital Diseases and Pregnancy Complications (150) · Genital Diseases (150) · Infections (150) · Bacterial Infections and Mycoses (149) · Female Urogenital Diseases (149) · Urogenital Diseases (149) · Genital Diseases, Female (148) · Bacterial Infections (147) · Vaginal Diseases (143) · Vaginitis (135) · Vulvar Diseases (23) · Mycoses (21) · Vulvitis (21) · Vulvovaginitis (19) · Candidiasis (16)
Metronidazole (33) · Benchmarking (4) · Clindamycin (4) · astodrimer (4) · Lacteol (3) · Probiotics (3) · Tinidazole (3) · Amphotericin B (2) · Azithromycin (2) · Ceftriaxone (2) · Control Groups (2) · Dequalinium (2) · Doxycycline (2) · Miconazole (2) · NuvaRing (2)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Starpharma Pty Ltd (5) · University of Pittsburgh (5) · Vaginal Biome Science (4) · Gedea Biotech AB (3) · Peking University Shenzhen Hospital (3) · Skaraborg Hospital (3) · Symbiomix Therapeutics (3) · University of Washington (3) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Daré Bioscience, Inc. (2) · Janneke van de Wijgert (2) · Karo Pharma AB (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Massachusetts General Hospital (2)
United States (55) · China (10) · Brazil (5) · Canada (5) · Kenya (5) · South Africa (5) · United Kingdom (5) · Italy (4) · Sweden (4) · Australia (3) · Czechia (3) · Germany (3) · India (3) · Israel (3) · Switzerland (3)
Jane Schwebke, MD (2) · Jeremy Paull, PhD (2) · Jeremy Paull, PhD. (2) · Ruifang Wu, M.D. (2) · Sharon L Hillier, PhD (2) · Abigail Norris Turner, PhD (1) · Ahmed R El-Adawy, Professor (1) · Aino Fianu Jonasson, Ass. Prof. (1) · Alan Bocking, MD, FRCSC (1) · Aleksandra M Cichonska, PhD (1) · Andrea Lojacono, MD (1) · Andrea R Thurman, MD (1) · Anke Hemmerling, MD, MPH, PhD (1) · Anne Macek, MD (1) · Ashwin Chatwani, MD (1)
PMID 21854593, PMID 15028938, PMID 16303068, PMID 17128343, PMID 17666604, PMID 18532873, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19616720, PMID 19936044, PMID 20370481, PMID 20591191, PMID 20644497, PMID 20801446, PMID 21216000, PMID 21489882, PMID 21992977, PMID 22059409, PMID 22205034, PMID 24949544, PMID 25935783, PMID 26137971, PMID 26210791, PMID 26611782, PMID 26635090, PMID 26911864, PMID 28697102, PMID 29474292, PMID 29912913, PMID 30002871, PMID 30184181, PMID 30597027, PMID 30807423, PMID 31189673, PMID 31404542, PMID 32402161, PMID 32434932, PMID 33050261, PMID 33207004, PMID 33514681, PMID 33939124, PMID 34560047, PMID 3485071, PMID 35113809, PMID 35675606, PMID 37098453, PMID 37471117, PMID 37575226, PMID 38154893
2023 (1), KL2RR025754 (1), P30AI027757 (1), R01AI058033 (1), R01AI170564 (1), R01HD077872 (1), R01HD098978 (1), R03TW005820 (1), R21AI111103 (1), U01HD040607 (1), U19AI113173 (1)